GlassScriptPhysician profile
Bipul Baibhav
NPI 1295983807
$99,611.03
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.26 · 2020: $1,166 · 2021: $5,886 · 2022: $9,463 · 2023: $35K · 2024: $33K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $8,309 · Consulting Fee: $4,921 · Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,035.00 |
| Travel and Lodging | $8,308.60 |
| Consulting Fee | $4,921.00 |
| Food and Beverage | $3,748.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $74,428.70 | 2022-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $11,448.29 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $8,087.31 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ge Healthcare | $1,587.16 | 2019-2023 | |
| Heartflow, INC. | $1,107.01 | 2025 | |
| Siemens Medical Solutions USA, INC. | $1,041.13 | 2024-2025 | Magnetom Sola, Naeotom Alpha |
| Novartis Pharmaceuticals Corporation | $440.08 | 2020-2025 | |
| Pfizer INC. | $298.49 | 2019-2025 | |
| Amgen INC. | $202.03 | 2022-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $187.02 | 2019-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $173.53 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.36 | 2021-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $103.85 | 2022-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.17 | 2019-2022 | |
| Abbott Laboratories | $40.34 | 2020-2024 | Perclose Prostyle |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.47 | 2023 | Verquvo |
| Irhythm Technologies, INC. | $29.56 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $26.60 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $24.61 | 2023 | Assure Wcd |
| Cvrx, INC. | $24.48 | 2023 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $21.94 | 2025 | |
| Astellas Pharma US INC | $21.44 | 2021 | |
| Scpharmaceuticals INC. | $18.81 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $16.61 | 2019 | |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipul Baibhav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.